Iron dysregulation in Huntington's disease

Huntington's disease (HD) is one of many neurodegenerative diseases with reported alterations in brain iron homeostasis that may contribute to neuropathogenesis. Iron accumulation in the specific brain areas of neurodegeneration in HD has been proposed based on observations in post‐mortem tissue and magnetic resonance imaging studies. Altered magnetic resonance imaging signal within specific brain regions undergoing neurodegeneration has been consistently reported and interpreted as altered levels of brain iron. Biochemical studies using various techniques to measure iron species in human samples, mouse tissue, or in vitro has generated equivocal data to support such an association. Whether elevated brain iron occurs in HD, plays a significant contributing role in HD pathogenesis, or is a secondary effect remains currently unclear.

[1]  Zbyszek Otwinowski,et al.  Secondary structure of Huntingtin amino-terminal region. , 2009, Structure.

[2]  M. Shimojo.  Huntingtin Regulates RE1-silencing Transcription Factor/Neuron-restrictive Silencer Factor (REST/NRSF) Nuclear Trafficking Indirectly through a Complex with REST/NRSF-interacting LIM Domain Protein (RILP) and Dynactin p150Glued* , 2008, Journal of Biological Chemistry.

[3]  J. Caboche,et al.  Multiple Aspects of Gene Dysregulation in Huntington’s Disease , 2013, Front. Neurol..

[4]  W. Webb,et al.  Neural Activity Triggers Neuronal Oxidative Metabolism Followed by Astrocytic Glycolysis , 2004, Science.

[5]  Danielle A. Simmons,et al.  Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease , 2007, Glia.

[6]  Z. Harris.  Aceruloplasminemia , 2003, Journal of the Neurological Sciences.

[7]  M. Tymianski,et al.  Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors. , 2003, Biochemical pharmacology.

[8]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[9]  P. Arosio,et al.  A Human Mitochondrial Ferritin Encoded by an Intronless Gene* , 2001, The Journal of Biological Chemistry.

[10]  P. Reddy,et al.  Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. , 2012, Biochimica et biophysica acta.

[11]  F. Crews,et al.  NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration , 2013, Glia.

[12]  M. MacDonald,et al.  Huntingtin inhibits caspase‐3 activation , 2006, The EMBO journal.

[13]  M. Hayden,et al.  Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity , 2004, Journal of Biological Chemistry.

[14]  R. Roos,et al.  The role of iron imaging in Huntington's disease. , 2013, International review of neurobiology.

[15]  J. Pujol,et al.  Biological significance of iron-related magnetic resonance imaging changes in the brain. , 1992, Archives of neurology.

[16]  F. Cicchetti,et al.  An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity , 2012, Cell Death and Disease.

[17]  R. Richards,et al.  Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. , 2007, Human molecular genetics.

[18]  K. Jellinger,et al.  The Role of Iron in Neurodegeneration , 1999, Drugs & aging.

[19]  J. Hodgson,et al.  Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. , 2001, American journal of human genetics.

[20]  G. Bartzokis,et al.  Increased basal ganglia iron levels in Huntington disease. , 1999, Archives of neurology.

[21]  M. MacDonald,et al.  Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. , 2000, Human molecular genetics.

[22]  T. Stemmler,et al.  A Cytosolic Iron Chaperone That Delivers Iron to Ferritin , 2008, Science.

[23]  F. Giorgini,et al.  Connecting the dots in Huntington's disease with protein interaction networks , 2005, Genome Biology.

[24]  M. Beal,et al.  Oxidative Stress in Huntington's Disease , 1999, Brain pathology.

[25]  R. Carraway,et al.  Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons , 1995, Neuron.

[26]  Timothy Edward John Behrens,et al.  In vivo evidence for the selective subcortical degeneration in Huntington's disease , 2009, NeuroImage.

[27]  M. Beal,et al.  Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  Michael P. Cusack,et al.  Huntingtin Phosphorylation Sites Mapped by Mass Spectrometry , 2006, Journal of Biological Chemistry.

[29]  P. Riederer,et al.  Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease , 2009, Neurotoxicity Research.

[30]  Francesco Scaravilli,et al.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease , 2004, Nature Genetics.

[31]  Serum iron, total iron binding capacity and ferritin in early huntington disease patients , 1994, Irish journal of medical science.

[32]  R. Fernández‐Bolaños,et al.  Important role of oxidative stress biomarkers in Huntington's disease. , 2011, Journal of medicinal chemistry.

[33]  C. Griesinger,et al.  Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Redensek,et al.  Iron homeostasis in astrocytes and microglia is differentially regulated by TNF‐α and TGF‐β1 , 2012, Glia.

[35]  A. Wyttenbach,et al.  In Vitro and in Vivo Aggregation of a Fragment of Huntingtin Protein Directly Causes Free Radical Production* , 2011, The Journal of Biological Chemistry.

[36]  Patrik Brundin,et al.  Huntington's disease: a synaptopathy? , 2003, Trends in molecular medicine.

[37]  M. Bear,et al.  Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity , 2000, Nature.

[38]  P. Aisen,et al.  Chemistry and biology of eukaryotic iron metabolism. , 2001, The international journal of biochemistry & cell biology.

[39]  Lu Gan,et al.  Palmitoylation of huntingtin by HIP14is essential for its trafficking and function , 2006, Nature Neuroscience.

[40]  D. Bredt,et al.  Nitric oxide signaling in the nervous system. , 1996, Methods in enzymology.

[41]  Paolo Arosio,et al.  Ferritins: a family of molecules for iron storage, antioxidation and more. , 2009, Biochimica et biophysica acta.

[42]  P. Arosio,et al.  Ferritin as an important player in neurodegeneration. , 2011, Parkinsonism & related disorders.

[43]  Shihua Li,et al.  Proteasomal dysfunction in aging and Huntington disease , 2011, Neurobiology of Disease.

[44]  Harry V. Vinters,et al.  The effect of formalin fixation on the levels of brain transition metals in archived samples , 2010, BioMetals.

[45]  P. Detloff,et al.  DNA instability in postmitotic neurons , 2008, Proceedings of the National Academy of Sciences.

[46]  Lu Gan,et al.  Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. , 2005, Human molecular genetics.

[47]  R A Knight,et al.  MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. , 1999, Radiology.

[48]  S. Hersch,et al.  Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine , 2013, PloS one.

[49]  A. Reiner,et al.  Relative Resistance of Striatal Neurons Containing Calbindin or Parvalbumin to Quinolinic Acid-Mediated Excitotoxicity Compared to Other Striatal Neuron Types , 1998, Experimental Neurology.

[50]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[51]  D. Sulzer,et al.  CARGO RECOGNITION FAILURE IS RESPONSIBLE FOR INEFFICIENT AUTOPHAGY IN HUNTINGTON’S DISEASE , 2010, Nature Neuroscience.

[52]  A. Tartakoff,et al.  Mechanisms of mammalian iron homeostasis. , 2012, Biochemistry.

[53]  S. Snyder,et al.  Rhes, a Striatal Specific Protein, Mediates Mutant-Huntingtin Cytotoxicity , 2009, Science.

[54]  T. Rouault.  Systemic iron metabolism: a review and implications for brain iron metabolism. , 2001, Pediatric neurology.

[55]  A. Cherubini,et al.  Seeking huntington disease biomarkers by multimodal, cross‐sectional basal ganglia imaging , 2013, Human brain mapping.

[56]  P. Wheeler,et al.  Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. , 2001, Pediatric neurology.

[57]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[58]  F. Coppedè,et al.  Genes and the Environment in Neurodegeneration , 2006, Bioscience reports.

[59]  S. Snyder,et al.  Rhes Deletion Is Neuroprotective in the 3-Nitropropionic Acid Model of Huntington's Disease , 2013, The Journal of Neuroscience.

[60]  C. Philpott.  Coming into View: Eukaryotic Iron Chaperones and Intracellular Iron Delivery* , 2012, The Journal of Biological Chemistry.

[61]  R H Myers,et al.  Decreased Neuronal and Increased Oligodendroglial Densities in Huntington's Disease Caudate Nucleus , 1991, Journal of neuropathology and experimental neurology.

[62]  Susan Lindquist,et al.  Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. , 2006, Human molecular genetics.

[63]  A. Bush.  Metal complexing agents as therapies for Alzheimer’s disease , 2002, Neurobiology of Aging.

[64]  S. Muller,et al.  Effects of the Ras homolog Rhes on Akt/protein kinase B and glycogen synthase kinase 3 phosphorylation in striatum , 2013, Neuroscience.

[65]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[66]  Christina H. Park,et al.  Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver* , 2001, The Journal of Biological Chemistry.

[67]  D. Manners,et al.  Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy , 2000, Annals of neurology.

[68]  J. Valentine,et al.  Misfolded CuZnSOD and amyotrophic lateral sclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[69]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[70]  J. Sutcliffe,et al.  Rhes: A striatal‐specific Ras homolog related to Dexras1 , 1999, Journal of neuroscience research.

[71]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[72]  D. Oorschot,et al.  Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. , 2010, Brain : a journal of neurology.

[73]  M. Hayden,et al.  Huntingtin is required for normal hematopoiesis. , 2000, Human molecular genetics.

[74]  Francesca M Chappell,et al.  Reliability of two techniques for assessing cerebral iron deposits with structural magnetic resonance imaging , 2011, Journal of magnetic resonance imaging : JMRI.

[75]  D. Butterfield,et al.  Nitric oxide in cell survival: a janus molecule. , 2009, Antioxidants & redox signaling.

[76]  Martin Drozda,et al.  Depletion of wild‐type huntingtin in mouse models of neurologic diseases , 2003, Journal of neurochemistry.

[77]  J. Pedraza-Chaverri,et al.  Iron porphyrinate Fe(TPPS) reduces brain cell damage in rats intrastriatally lesioned by quinolinate. , 2008, Neurotoxicology and teratology.

[78]  C. Chen.  Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington's disease. , 2011, Chang Gung medical journal.

[79]  Elena Cattaneo,et al.  Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.

[80]  Elizabeta Nemeth,et al.  IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. , 2004, The Journal of clinical investigation.

[81]  U. Brunk,et al.  Intralysosomal iron chelation protects against oxidative stress‐induced cellular damage , 2006, The FEBS journal.

[82]  D. Rubinsztein,et al.  Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases , 2005, The Journal of cell biology.

[83]  Blair R. Leavitt,et al.  Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease , 2002, The Journal of Neuroscience.

[84]  A. Parent,et al.  Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene , 1999, Brain Research.

[85]  J. Pedraza-Chaverri,et al.  Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease , 2009, Behavioural Brain Research.

[86]  S. Snyder,et al.  NMDA Receptor-Nitric Oxide Transmission Mediates Neuronal Iron Homeostasis via the GTPase Dexras1 , 2006, Neuron.

[87]  B. Paw,et al.  Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria , 2009, Proceedings of the National Academy of Sciences.

[88]  R Bakshi,et al.  MRI T2 shortening (‘black T2’) in multiple sclerosis: frequency, location, and clinical correlation , 2000, Neuroreport.

[89]  A. Gregory,et al.  Genetics of Neurodegeneration with Brain Iron Accumulation , 2011, Current neurology and neuroscience reports.

[90]  David M. Wilson,et al.  Stoichiometry of Base Excision Repair Proteins Correlates with Increased Somatic CAG Instability in Striatum over Cerebellum in Huntington's Disease Transgenic Mice , 2009, PLoS genetics.

[91]  G. Bartzokis,et al.  MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. , 2000, Cellular and molecular biology.

[92]  M. MacDonald,et al.  The serum‐ and glucocorticoid‐induced kinase SGK inhibits mutant huntingtin‐induced toxicity by phosphorylating serine 421 of huntingtin , 2004, The European journal of neuroscience.

[93]  L. Raymond,et al.  Polyglutamine-Modulated Striatal Calpain Activity in YAC Transgenic Huntington Disease Mouse Model: Impact on NMDA Receptor Function and Toxicity , 2008, The Journal of Neuroscience.

[94]  Jane S. Paulsen,et al.  Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. , 2011, Brain : a journal of neurology.

[95]  D. Rubinsztein,et al.  Wild type huntingtin reduces the cellular toxicity of mutant huntingtin in mammalian cell models of Huntington's disease , 2001, Journal of medical genetics.

[96]  Blaine R. Roberts,et al.  Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export , 2012, Nature Medicine.

[97]  F. Saudou,et al.  Vesicular Glycolysis Provides On-Board Energy for Fast Axonal Transport , 2013, Cell.

[98]  G. Reynolds,et al.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.

[99]  Mark A. Smith,et al.  Oxidative posttranslational modifications in Alzheimer disease , 1996, Molecular and chemical neuropathology.

[100]  D. Rubinsztein,et al.  Deletion of the Huntingtin Polyglutamine Stretch Enhances Neuronal Autophagy and Longevity in Mice , 2010, PLoS genetics.

[101]  A. Joyner,et al.  Inactivation of the mouse Huntington's disease gene homolog Hdh. , 1995, Science.

[102]  O. Zuffardi,et al.  Ring syndrome: still true? , 2008, Journal of Medical Genetics.

[103]  E. Cattaneo,et al.  Role of brain-derived neurotrophic factor in Huntington's disease , 2007, Progress in Neurobiology.

[104]  Elsdon Storey,et al.  Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization , 1993, Experimental Neurology.

[105]  David H Salat,et al.  Alterations in brain transition metals in Huntington disease: an evolving and intricate story. , 2012, Archives of neurology.

[106]  M. Youdim,et al.  Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28 , 2004, Annals of the New York Academy of Sciences.

[107]  P. Riederer,et al.  The possible role of iron in the etiopathology of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[108]  P. Greengard,et al.  Neuronal and behavioural abnormalities in striatal function in DARPP‐32‐mutant mice , 1999, The European journal of neuroscience.

[109]  Steven Finkbeiner,et al.  Single Neuron Ubiquitin-Proteasome Dynamics Accompanying Inclusion Body Formation in Huntington Disease* , 2009, Journal of Biological Chemistry.

[110]  I. Moseley,et al.  Signal intensity on MRI of basal ganglia in multiple sclerosis. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[111]  M. Aschner,et al.  Altered manganese homeostasis and manganese toxicity in a Huntington's disease striatal cell model are not explained by defects in the iron transport system. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[112]  R. Truant,et al.  Huntingtin contains a highly conserved nuclear export signal. , 2003, Human molecular genetics.

[113]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[114]  J. Gusella,et al.  Huntington's disease. Pathogenesis and management. , 1986, The New England journal of medicine.

[115]  D J Brooks,et al.  Microglial activation correlates with severity in Huntington disease , 2006, Neurology.

[116]  T. Ganz,et al.  Hepcidin and disorders of iron metabolism. , 2011, Annual review of medicine.

[117]  C. Ríos,et al.  Free Copper, Ferroxidase and SOD1 Activities, Lipid Peroxidation and NOx Content in the CSF. A Different Marker Profile in Four Neurodegenerative Diseases , 2008, Neurochemical Research.

[118]  S. David,et al.  Glycosylphosphatidylinositol-anchored Ceruloplasmin Is Required for Iron Efflux from Cells in the Central Nervous System* , 2003, Journal of Biological Chemistry.

[119]  I. Ferrer,et al.  Proteomic and oxidative stress analysis in human brain samples of Huntington disease. , 2008, Free radical biology & medicine.

[120]  J. Caboche,et al.  Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments , 2008, Current opinion in neurology.

[121]  G. Weiss.  Iron metabolism in the anemia of chronic disease. , 2009, Biochimica et biophysica acta.

[122]  J. Penney,et al.  Trinucleotide repeat length instability and age of onset in Huntington's disease , 1993, Nature Genetics.

[123]  Michael S. Levine,et al.  Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.

[124]  D. Altschuh,et al.  Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions. , 2011, Human molecular genetics.

[125]  J. Coyle,et al.  Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington's Disease1 , 1977, Journal of neurochemistry.

[126]  O. Gokce,et al.  Decreased Striatal RGS2 Expression Is Neuroprotective in Huntington's Disease (HD) and Exemplifies a Compensatory Aspect of HD-Induced Gene Regulation , 2011, PloS one.

[127]  J. Lucas,et al.  Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. , 2010, Free radical biology & medicine.

[128]  M. Youdim,et al.  Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. , 2000, Cellular and molecular biology.

[129]  R. Schwarcz,et al.  Regulation of quinolinic acid neosynthesis in mouse, rat and human brain by iron and iron chelators in vitro , 2012, Journal of Neural Transmission.

[130]  Andrea Cherubini,et al.  Aging of subcortical nuclei: Microstructural, mineralization and atrophy modifications measured in vivo using MRI , 2009, NeuroImage.

[131]  P. Pandolfi,et al.  SUMO Modification of Huntingtin and Huntington's Disease Pathology , 2004, Science.

[132]  Chris Frost,et al.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis , 2011, The Lancet Neurology.

[133]  M. Beal,et al.  Bioenergetic and oxidative stress in neurodegenerative diseases. , 1995, Life sciences.

[134]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[135]  S. Floresco,et al.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.

[136]  T. Ganz,et al.  Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. , 2012, Cell metabolism.

[137]  R. Albin,et al.  Genetics and molecular biology of Huntington's disease , 1995, Trends in Neurosciences.

[138]  A. Hackam,et al.  Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease , 2004, Cell Death and Differentiation.

[139]  S. Luquet,et al.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. , 2006, Cell metabolism.

[140]  S. Zeitlin,et al.  Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. , 1998, Development.

[141]  S. Ropele,et al.  Quantitative MR imaging of brain iron: a postmortem validation study. , 2010, Radiology.

[142]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[143]  F. Sanvito,et al.  Mitochondrial Ferritin Expression in Adult Mouse Tissues , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[144]  S. Snyder,et al.  Dexras1, a Small GTPase, Is Required for Glutamate-NMDA Neurotoxicity , 2013, The Journal of Neuroscience.

[145]  N Makris,et al.  Striatal volume loss in HD as measured by MRI and the influence of CAG repeat , 2001, Neurology.

[146]  Rohit Bakshi,et al.  Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. , 2005, Archives of neurology.

[147]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[148]  H. Lehrach,et al.  A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. , 2004, Molecular cell.

[149]  Andrew G. Webb,et al.  Elevated brain iron is independent from atrophy in Huntington's Disease , 2012, NeuroImage.

[150]  A. Albertini,et al.  Human ferritin H‐chains can be obtained in non‐assembled stable forms which have ferroxidase activity , 1993, FEBS letters.

[151]  Françoise Condé,et al.  Replicating Huntington's disease phenotype in experimental animals , 1999, Progress in Neurobiology.

[152]  M. Edwards,et al.  Hereditary haemochromatosis is unlikely to cause movement disorders , 2004, Journal of Neurology.

[153]  R. Roos,et al.  Basal ganglia volume and clinical correlates in ‘preclinical’ Huntington’s disease , 2008, Journal of Neurology.

[154]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.

[155]  R. Atwal,et al.  Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. , 2007, Human molecular genetics.

[156]  V. Silani,et al.  Huntington's disease: The current state of research with peripheral tissues , 2009, Experimental Neurology.

[157]  Jian Wang,et al.  Regulation of cellular iron metabolism , 2011, The Biochemical journal.

[158]  David S Tuch,et al.  Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures , 2006, Movement disorders : official journal of the Movement Disorder Society.

[159]  J. Connor,et al.  Relationship of iron to oligodendrocytes and myelination. , 1996, Glia.

[160]  R. Bakshi,et al.  Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients , 2001, Journal of the Neurological Sciences.

[161]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[162]  R. Roos,et al.  MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease , 2010, PLoS currents.

[163]  D. Houitte,et al.  A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin , 2013, Human molecular genetics.

[164]  M. Hayden,et al.  Testicular degeneration in Huntington disease , 2007, Neurobiology of Disease.

[165]  S. Folstein,et al.  Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. , 1995, American journal of human genetics.

[166]  R. Truant,et al.  Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin , 2013, Proceedings of the National Academy of Sciences.

[167]  Xudong Huang,et al.  The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. , 1999, Biochemistry.

[168]  Jim Mintz,et al.  Myelin Breakdown and Iron Changes in Huntington’s Disease: Pathogenesis and Treatment Implications , 2007, Neurochemical Research.

[169]  J. Pedraza-Chaverri,et al.  Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington’s disease in rats: Protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III) , 2005, Neuroscience.

[170]  D. McLachlan,et al.  Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.

[171]  I. Bezprozvanny.  Calcium signaling and neurodegenerative diseases. , 2009, Trends in molecular medicine.

[172]  X. Gu,et al.  In silico analysis indicates a similar gene expression pattern between human brain and testis , 2004, Cytogenetic and Genome Research.

[173]  S. Snyder,et al.  Rhes, a Striatal-selective Protein Implicated in Huntington Disease, Binds Beclin-1 and Activates Autophagy* , 2013, The Journal of Biological Chemistry.

[174]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[175]  Wilhelm Gaus,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.

[176]  C. Vulpe,et al.  Iron Efflux from Oligodendrocytes Is Differentially Regulated in Gray and White Matter , 2011, The Journal of Neuroscience.

[177]  A. Parent,et al.  Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington’s disease , 2000, Brain Research Reviews.

[178]  Z. Qin,et al.  Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[179]  R A Brooks,et al.  The quantitative Relation Between T1‐Weighted and T2‐Weighted MRI of Normal gray Matter and iron concentration , 1995, Journal of magnetic resonance imaging : JMRI.

[180]  Erich E Wanker,et al.  The hunt for huntingtin function: interaction partners tell many different stories. , 2003, Trends in biochemical sciences.

[181]  A. Ludolph,et al.  Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[182]  K. Pantopoulos,et al.  Regulation of iron transport and the role of transferrin. , 2012, Biochimica et biophysica acta.

[183]  Carlos Cepeda,et al.  The corticostriatal pathway in Huntington's disease , 2007, Progress in Neurobiology.

[184]  R. Currie,et al.  Huntingtin inclusion bodies are iron‐dependent centers of oxidative events , 2006, The FEBS journal.

[185]  M. MacDonald,et al.  Huntington's disease: the case for genetic modifiers , 2009, Genome Medicine.

[186]  D. Surmeier,et al.  Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons , 1996, The Journal of Neuroscience.

[187]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[188]  M. Harada,et al.  Wilson disease , 2002, Medical Electron Microscopy.

[189]  G. Lahoste,et al.  Attenuation of Rhes Activity Significantly Delays the Appearance of Behavioral Symptoms in a Mouse Model of Huntington's Disease , 2013, PloS one.

[190]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[191]  E. Růžička,et al.  MR relaxometry in Huntington's disease: Correlation between imaging, genetic and clinical parameters , 2007, Journal of the Neurological Sciences.

[192]  S. Finkbeiner,et al.  IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome , 2009, The Journal of cell biology.

[193]  Rohit Bakshi,et al.  Iron in chronic brain disorders: Imaging and neurotherapeutic implications , 2007, Neurotherapeutics.

[194]  D. Legrand,et al.  Lactotransferrin binding to its platelet receptor inhibits platelet aggregation. , 1993, European journal of biochemistry.

[195]  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2003 .

[196]  John F Schenck,et al.  Magnetic resonance imaging of brain iron , 2003, Journal of the Neurological Sciences.

[197]  M. Fleming,et al.  Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism. , 2009, Blood.

[198]  K. Cousins,et al.  Paradoxical effects of copper and manganese on brain mitochondrial function. , 2001, Life sciences.

[199]  M. Hayden,et al.  Wild‐type huntingtin protects neurons from excitotoxicity , 2006, Journal of neurochemistry.

[200]  L Gan,et al.  HIP1 Functions in Clathrin-mediated Endocytosis through Binding to Clathrin and Adaptor Protein 2* , 2001, The Journal of Biological Chemistry.

[201]  Nick C Fox,et al.  Whole‐brain atrophy as a measure of progression in premanifest and early Huntington's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[202]  M. MacDonald,et al.  Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. , 2004, Human molecular genetics.

[203]  M. Hayden,et al.  Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk , 2014, Movement disorders : official journal of the Movement Disorder Society.

[204]  Joanna M. Wardlaw,et al.  Reliability of two techniques for assessing cerebral iron deposits from structural MRI , 2011 .

[205]  A. Valencia,et al.  The small GTP-binding protein, Rhes, regulates signal transduction from G protein-coupled receptors , 2004, Oncogene.

[206]  A. Schapira,et al.  Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease. , 2004, Methods in molecular biology.

[207]  Guanghua Zhao,et al.  Iron(II) and hydrogen peroxide detoxification by human H-chain ferritin. An EPR spin-trapping study. , 2006, Biochemistry.

[208]  W H Oldendorf,et al.  Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores , 1993, Magnetic resonance in medicine.

[209]  F. Walker,et al.  Does hereditary hemochromatosis influence the age of onset of Huntington's disease? , 2010 .

[210]  K. Uğurbil,et al.  Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts , 2007, Movement disorders : official journal of the Movement Disorder Society.

[211]  M. MacDonald,et al.  Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. , 2000, Human molecular genetics.

[212]  K. Kaida,et al.  [Reduced signal intensity of T2 weighted MR imaging of thalamus and putamen in multiple sclerosis in Japan]. , 2000, Rinsho shinkeigaku = Clinical neurology.

[213]  M. Hayden,et al.  Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. , 2005, Human molecular genetics.

[214]  J. Hodgson,et al.  Huntingtin Is Ubiquitinated and Interacts with a Specific Ubiquitin-conjugating Enzyme* , 1996, The Journal of Biological Chemistry.

[215]  S. Snyder,et al.  Golgi protein ACBD3 mediates neurotoxicity associated with Huntington's disease. , 2013, Cell reports.

[216]  J. Roder,et al.  NMDA Receptor Function and NMDA Receptor-Dependent Phosphorylation of Huntingtin Is Altered by the Endocytic Protein HIP1 , 2007, The Journal of Neuroscience.

[217]  M. MacDonald,et al.  Huntington's disease: translating a CAG repeat into a pathogenic mechanism , 1996, Current Opinion in Neurobiology.

[218]  M. Hayden,et al.  CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease , 2013, Journal of Medical Genetics.

[219]  M. Pandolfo,et al.  Deferiprone for the treatment of Friedreich's ataxia , 2013, Journal of neurochemistry.

[220]  E. Nagata,et al.  Autophagosome-like vacuole formation in Huntington's disease lymphoblasts , 2004, Neuroreport.

[221]  K. Coffman,et al.  Secondary , 2020, Definitions.

[222]  D. Praticò,et al.  The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. , 2011, Investigative ophthalmology & visual science.

[223]  J. Cheah,et al.  PKA modulates iron trafficking in the striatum via small GTPase, Rhes , 2013, Neuroscience.

[224]  D. Rubinsztein,et al.  Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. , 2002, Human molecular genetics.

[225]  E. Cabiscol,et al.  Protein oxidation in Huntington disease , 2012, BioFactors.

[226]  Peng Lei,et al.  A delicate balance: Iron metabolism and diseases of the brain , 2013, Front. Aging Neurosci..

[227]  Michael R. Hayden,et al.  Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin , 2009, Nature Medicine.

[228]  A. Hackam,et al.  Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3 , 2000, The Journal of Neuroscience.

[229]  R. Llinás,et al.  Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[230]  L. Fleisher,et al.  Iron alters glutamate secretion by regulating cytosolic aconitase activity. , 2005, American journal of physiology. Cell physiology.

[231]  T. Montine,et al.  Cerebrospinal fluid F2-isoprostanes are elevated in Huntington’s disease , 1999, Neurology.

[232]  M. Hayden,et al.  Body weight is modulated by levels of full-length huntingtin. , 2006, Human molecular genetics.

[233]  D. Birchall,et al.  Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. , 2006, Brain : a journal of neurology.

[234]  D. Pow,et al.  Expression of multiple glutamate transporter splice variants in the rodent testis. , 2011, Asian journal of andrology.

[235]  E. Tolosa,et al.  Expression of Brain-Derived Neurotrophic Factor in Cortical Neurons Is Regulated by Striatal Target Area , 2001, The Journal of Neuroscience.

[236]  M. Hayden,et al.  Huntingtin and Huntingtin-Associated Protein 1 Influence Neuronal Calcium Signaling Mediated by Inositol-(1,4,5) Triphosphate Receptor Type 1 , 2003, Neuron.

[237]  A. Koeppen,et al.  The history of iron in the brain , 1995, Journal of the Neurological Sciences.

[238]  S. Hersch,et al.  Mechanisms of Copper Ion Mediated Huntington's Disease Progression , 2007, PloS one.

[239]  P. Harrison,et al.  The ferritins: molecular properties, iron storage function and cellular regulation. , 1996, Biochimica et biophysica acta.

[240]  T. Rouault,et al.  Iron metabolism in the CNS: implications for neurodegenerative diseases , 2013, Nature Reviews Neuroscience.

[241]  P Riederer,et al.  Iron in the Parkinsonian substantia nigra. , 1997, Movement disorders : official journal of the Movement Disorder Society.

[242]  D. Rubinsztein,et al.  Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number. , 1993, Human molecular genetics.

[243]  M. MacDonald,et al.  Heterogeneous Topographic and Cellular Distribution of Huntingtin Expression in the Normal Human Neostriatum , 1997, The Journal of Neuroscience.

[244]  D. Richardson,et al.  Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol , 2010, Proceedings of the National Academy of Sciences.

[245]  S. Finkbeiner,et al.  Protein aggregates in Huntington's disease , 2012, Experimental Neurology.

[246]  M. Aschner,et al.  Disease‐toxicant screen reveals a neuroprotective interaction between Huntington’s disease and manganese exposure , 2010, Journal of neurochemistry.

[247]  Torsten Rohlfing,et al.  MRI estimates of brain iron concentration in normal aging: Comparison of field-dependent (FDRI) and phase (SWI) methods , 2009, NeuroImage.

[248]  Luisa Mola Morales,et al.  Serum ferritin deficiency in Huntington's disease patients , 1991, Neuroscience Letters.

[249]  M. MacDonald,et al.  The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. , 2001, Human molecular genetics.

[250]  C. Sheline,et al.  Cu2+ toxicity inhibition of mitochondrial dehydrogenases in vitro and in vivo , 2004, Annals of neurology.

[251]  A. Hamby,et al.  Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[252]  Dean Y. Li,et al.  Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. , 2010, The Journal of clinical investigation.

[253]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[254]  A. Townsend,et al.  Hepcidin regulation by innate immune and infectious stimuli. , 2011, Blood.

[255]  Jim Mintz,et al.  Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases , 2005, Alzheimer's & Dementia.

[256]  C. Schwarz,et al.  Wild-Type and Mutant Huntingtins Function in Vesicle Trafficking in the Secretory and Endocytic Pathways , 1998, Experimental Neurology.

[257]  J. Penney,et al.  Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study , 2004, Journal of Chemical Neuroanatomy.

[258]  S. Schneider,et al.  Neuroimaging Features of Neurodegeneration with Brain Iron Accumulation , 2012, American Journal of Neuroradiology.

[259]  P. Reddy,et al.  Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.

[260]  K. Lindenberg,et al.  Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. , 2002, Molecular cell.

[261]  E. Hirsch,et al.  Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. , 2006, Molecular biology of the cell.

[262]  D. Rigamonti,et al.  Huntingtin's Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing* , 2001, The Journal of Biological Chemistry.

[263]  Glyn Johnson,et al.  Magnetic field correlation imaging , 2006, Magnetic resonance in medicine.

[264]  Jane S. Paulsen,et al.  Striatal and white matter predictors of estimated diagnosis for Huntington disease , 2010, Brain Research Bulletin.

[265]  C. Parsons,et al.  Expression of Polyglutamine-expanded Huntingtin Induces Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors* , 2003, Journal of Biological Chemistry.

[266]  K. Pantopoulos.  Iron Metabolism and the IRE/IRP Regulatory System: An Update , 2004, Annals of the New York Academy of Sciences.

[267]  R. Roos,et al.  Somatic expansion of the (CAG)n repeat in Huntington disease brains , 1995, Human Genetics.

[268]  J. Penney,et al.  Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. , 1990, The New England journal of medicine.

[269]  G. Lahoste,et al.  The Ras homolog Rhes affects dopamine D1 and D2 receptor-mediated behavior in mice , 2008, Neuroreport.

[270]  C. Masters,et al.  Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. , 1999, The Journal of biological chemistry.

[271]  M. Chesselet,et al.  Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.

[272]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[273]  D. Ehrnhoefer,et al.  Mouse models of Huntington disease: variations on a theme , 2009, Disease Models & Mechanisms.

[274]  P. Greengard,et al.  DARPP-32 knockout mice exhibit impaired reversal learning in a discriminated operant task , 2000, Brain Research.

[275]  Jane S. Paulsen,et al.  Preclinical Huntington's disease: Compensatory brain responses during learning , 2006, Annals of neurology.

[276]  R H Myers,et al.  Quantitative neuropathological changes in presymptomatic Huntington's disease , 2001, Annals of neurology.

[277]  J. Gitlin,et al.  Use of desferrioxamine in the treatment of aceruloplasminemia , 1997, Annals of neurology.

[278]  C. Gissi,et al.  Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive polyQ in sea urchin. , 2008, Molecular biology and evolution.

[279]  Howard Schulman,et al.  Global changes to the ubiquitin system in Huntington's disease , 2007, Nature.

[280]  B. Drayer,et al.  Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? , 1987, AJR. American journal of roentgenology.

[281]  Peter Schulz-Knappe,et al.  LEAP‐1, a novel highly disulfide‐bonded human peptide, exhibits antimicrobial activity , 2000, FEBS letters.

[282]  Sarah J Tabrizi,et al.  Huntington’s disease , 2010, BMJ : British Medical Journal.